OCGN
Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.88
+18.04%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.81
From 52W high−64.53%
Volume5.31M
Market cap$298.28M
P/E (TTM)—
P/S (TTM)65.1x
Div yield—
Key dataNov 4, 2026
Open
$0.81
From 52W high
−64.53%
Volume
5.31M
Market cap
$298.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.1x
P/E (TTM)
—
RSI (14)
44.3
MomentumView details →
1D Return
+18.04%
YTD Return
−40.33%
SummaryUpdated Jun 1, 2026
Ocugen, Inc. (NASDAQ:OCGN) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Malvern, Pennsylvania. The company went public in December 2014 and has evolved from its initial focus on COVID-19 vaccines to become a specialized developer of gene therapies for inherited retinal diseases. Ocugen is currently advancing multiple clinical programs targeting various forms of blindness, with three potential biologics license applications planned for filing within the next three years.
Similar companies
Latest newsMore news →
Ocugen, Inc. reported a third-quarter loss of $0.06 per share, compared with a loss of $0.07 per share a year earlier, in line with the consensus estimate.3h agoOcugen, Inc. executed an exclusive license agreement for OCU400 in the Middle East and North Africa with Roots Pharmaceutical.6h agoOcugen, Inc. executed an agreement with Global Alliance for Regenerative Medicine to coordinate and manage patient care for OCU400 in The Bahamas.6h ago